Trial Profile

A Randomised, Double-Blind, Multicentre Dose-Finding Phase IIb Study for Up to 8 Weeks' Treatment With AZD0865 25, 50, 75 Mg and Esomeprazole 40 Mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects With GERD With Erosive Esophagitis According to the LA Classification in Adult Subjects.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 0865 (Primary) ; Esomeprazole
Indications Erosive oesophagitis; Gastro-oesophageal reflux; Heartburn; Reflux oesophagitis
Focus Therapeutic Use
Sponsors AstraZeneca

18 Mar 2010 Patient segment added, and title amended to treat erosive-oesophagitis.
25 Aug 2009 Actual initiation date (May 2004) and actual end date (Mar 2005) added as reported by ClinicalTrials.gov
11 Sep 2008 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com